PL4212152T3 - Schemat dawkowania sakubitrylu-walsartanu do leczenia przewlekłej skurczowej niewydolności serca - Google Patents

Schemat dawkowania sakubitrylu-walsartanu do leczenia przewlekłej skurczowej niewydolności serca

Info

Publication number
PL4212152T3
PL4212152T3 PL23154757.1T PL23154757T PL4212152T3 PL 4212152 T3 PL4212152 T3 PL 4212152T3 PL 23154757 T PL23154757 T PL 23154757T PL 4212152 T3 PL4212152 T3 PL 4212152T3
Authority
PL
Poland
Prior art keywords
sacubitril
heart failure
dosage regimen
treating chronic
systolic heart
Prior art date
Application number
PL23154757.1T
Other languages
English (en)
Inventor
Adel Redmond RIZKALA
Victor Chengwei Shi
Fabian CHEN
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55967342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4212152(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL4212152T3 publication Critical patent/PL4212152T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL23154757.1T 2015-05-11 2016-05-09 Schemat dawkowania sakubitrylu-walsartanu do leczenia przewlekłej skurczowej niewydolności serca PL4212152T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562159703P 2015-05-11 2015-05-11

Publications (1)

Publication Number Publication Date
PL4212152T3 true PL4212152T3 (pl) 2025-08-11

Family

ID=55967342

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16722388.2T PL3294283T3 (pl) 2015-05-11 2016-05-09 Schemat dawkowania sakubitrylu-walsartanu do leczenia niewydolności serca
PL23154757.1T PL4212152T3 (pl) 2015-05-11 2016-05-09 Schemat dawkowania sakubitrylu-walsartanu do leczenia przewlekłej skurczowej niewydolności serca

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16722388.2T PL3294283T3 (pl) 2015-05-11 2016-05-09 Schemat dawkowania sakubitrylu-walsartanu do leczenia niewydolności serca

Country Status (15)

Country Link
US (2) US11058667B2 (pl)
EP (3) EP4212152B1 (pl)
JP (1) JP6576469B2 (pl)
CY (1) CY1126036T1 (pl)
DK (2) DK3294283T3 (pl)
ES (2) ES2945866T3 (pl)
FI (2) FI4212152T3 (pl)
HR (2) HRP20230480T1 (pl)
HU (2) HUE071910T2 (pl)
LT (2) LT3294283T (pl)
PL (2) PL3294283T3 (pl)
PT (2) PT3294283T (pl)
RS (2) RS64242B1 (pl)
SI (2) SI4212152T1 (pl)
WO (1) WO2016181284A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
EP3117823A1 (en) * 2015-07-17 2017-01-18 Quimica Sintetica, S.A. Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
CN113286585B (zh) * 2019-09-20 2022-11-08 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
WO2021230664A1 (ko) * 2020-05-12 2021-11-18 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CA2472399C (en) 2002-01-17 2012-02-21 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
PL2295035T3 (pl) 2007-11-06 2016-11-30 Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep)
MX378867B (es) 2012-08-24 2025-03-11 Novartis Ag Inhibidores de la nep para el tratamiento de enfermedades caracterizadas por el ensanchamiento o remodelacion auricular.
HRP20200060T1 (hr) 2013-08-26 2020-04-03 Novartis Ag Nova uporaba
JP2016530282A (ja) 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca

Also Published As

Publication number Publication date
DK4212152T3 (da) 2025-06-23
EP4570314A2 (en) 2025-06-18
JP2018519266A (ja) 2018-07-19
DK3294283T3 (da) 2023-05-30
PT4212152T (pt) 2025-07-08
RS66936B1 (sr) 2025-07-31
HUE071910T2 (hu) 2025-10-28
HUE062195T2 (hu) 2023-10-28
PT3294283T (pt) 2023-06-07
PL3294283T3 (pl) 2023-07-24
LT3294283T (lt) 2023-06-12
US20180125820A1 (en) 2018-05-10
WO2016181284A1 (en) 2016-11-17
EP4212152A1 (en) 2023-07-19
ES3034658T3 (en) 2025-08-21
FI3294283T3 (fi) 2023-05-24
FI4212152T3 (fi) 2025-07-11
HRP20250779T1 (hr) 2025-08-29
SI3294283T1 (sl) 2023-07-31
LT4212152T (lt) 2025-07-10
HRP20230480T1 (hr) 2023-07-21
US20220133694A1 (en) 2022-05-05
EP3294283B1 (en) 2023-03-08
ES2945866T3 (es) 2023-07-10
EP4212152B1 (en) 2025-04-30
SI4212152T1 (sl) 2025-08-29
EP4570314A3 (en) 2025-09-10
RS64242B1 (sr) 2023-06-30
EP3294283A1 (en) 2018-03-21
JP6576469B2 (ja) 2019-09-18
US11058667B2 (en) 2021-07-13
CY1126036T1 (el) 2023-11-15

Similar Documents

Publication Publication Date Title
LT4212152T (lt) Sakubitrilo ir valsartano dozavimo režimas, skirtas lėtinio sistolinio širdies nepakankamumo gydymui
IL246426B (en) Catheter with a double basket
SG10201913800UA (en) Patient interfaces
PL3256076T3 (pl) Urządzenia do dokowania zastawki serca
GB201509338D0 (en) Combination therapy
ZA201802452B (en) New therapeutic strategies against blood cancer
PL3363428T3 (pl) Perfuzyjna postać dawkowania
IL247084B (en) dose fgh–18
GB201521217D0 (en) Dosage regimens
GB201511210D0 (en) Heart Biotech Pharma Limited
SG10202008024VA (en) Method for Treating Heart Failure
GB201514303D0 (en) Bifidobacteria for treating cardiac conditions
GB201418710D0 (en) Dosage regimen
PT3324951T (pt) Fluido terapêutico peritoneal
GB201514302D0 (en) Lactobacilli for treating cardiac dysfunction
GB201502209D0 (en) Filovirus therapy
LT3139932T (lt) Gydymo režimas su tiakumicino junginiu
GB201512101D0 (en) Therapeutic treatments
GB201512103D0 (en) Therapeutic treatments
GB201521216D0 (en) Dosage regimen
GB201506944D0 (en) Therapeutic treatment
GB201617850D0 (en) Dosage regimen
HU4542U (en) Therapeutic furniture
GB201507717D0 (en) Treatment couch
GB201610502D0 (en) Dosage regimen